Q32 Bio Inc. Announces Results of 2026 Annual Meeting of Stockholders

On June 12, 2026, Q32 Bio Inc. held its 2026 Annual Meeting of Stockholders. During the meeting, stockholders voted on three key proposals. First, stockholders elected Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D., as Class II directors for three-year terms expiring in 2029. Second, the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Finally, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. A total of 11,833,800 shares of common stock were represented at the meeting, accounting for approximately 75.71% of the total shares outstanding as of the April 15, 2026 record date. The filing confirms the standard governance activities and executive compensation approvals typical of an annual meeting. no clinical data or material business updates were disclosed in this report.